Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy

被引：0
|
作者：
Paulus, Aneel
Manna, Alak
Wang, Hengbang
Chen, Jianyong
Min, Ping
Yin, Yan
Dutta, Navnita
Halder, Nabanita
Ciccio, Gina
Copland, John
Han, Bing
Bai, Longchuan
Liu, Liu
Wang, Mi
McEachern, Donna
Przybranowski, Sally
Yang, Chao-Yie
Stuckey, Jeanne
Wu, Depei
Li, Caixia
Ryan, Jeremy
Letai, Anthony
Ailawadhi, Sikander
Yang, Dajun
Wang, Shaomeng
Chanan-Khan, Asher
Zhai, Yifan
机构：
来源：
LEUKEMIA & LYMPHOMA | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1549996
引用
收藏
页码：S79 / S79
页数：1
相关论文
共 50 条
  • [1] Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
    Deng, Jing
    Paulus, Aneel
    Fang, Douglas D.
    Manna, Alak
    Wang, Guangfeng
    Wang, Hengbang
    Zhu, Saijie
    Chen, Jianyong
    Min, Ping
    Yin, Yan
    Dutta, Navnita
    Halder, Nabanita
    Ciccio, Gina
    Copland III, John A.
    Miller, James
    Han, Bing
    Bai, Longchuan
    Liu, Liu
    Wang, Mi
    McEachern, Donna
    Przybranowski, Sally
    Yang, Chao-Yie
    Stuckey, Jeanne A.
    Wu, Depei
    Li, Caixia
    Ryan, Jeremy
    Letai, Anthony
    Ailawadhi, Sikander
    Yang, Dajun
    Wang, Shaomeng
    Chanan-Khan, Asher
    Zhai, Yifan
    CLINICAL CANCER RESEARCH, 2022, 28 (24) : 5455 - 5468
  • [2] Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Treatment of Patients with Myelodysplastic Syndrome (MDS)
    Wang, Huafeng
    Wei, Xudong
    Liang, Yang
    Weng, Jianyu
    He, Wenjuan
    Chang, Chunkang
    Chen, Suning
    Ma, Hongbing
    Chen, Zi
    Men, Lichuang
    Liu, Lihui
    Tian, Xiaohong
    Zhang, Zhang
    Cong, Danhua
    Yang, Dajun
    Zhai, Yifan
    Jin, Jie
    BLOOD, 2024, 144 : 3202 - 3203
  • [3] First-in-Human Study of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Patients With Relapsed/Refractory CLL and Other Hematologic Malignancies
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (07) : 10 - 11
  • [4] Synergistic antitumor activity of lisaftoclax (APG-2575) and alrizomadlin (APG-115) through dual targeting of BCL-2/MDM2-P53 apoptotic pathways in preclinical models of acute myeloid leukemia
    Fang, Douglas D.
    Tang, Qiuqiong
    Wang, Qixin
    Li, Na
    Zhou, Feng
    Zhai, Guoqin
    Yin, Yan
    Yang, Dajun
    Zhai, Yifan
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [5] Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia
    Wei, Wenwen
    Huang, Shujuan
    Ling, Qing
    Mao, Shihui
    Qian, Yu
    Ye, Wenle
    Li, Fenglin
    Pan, Jiajia
    Lin, Xiangjie
    Huang, Jiansong
    Huang, Xin
    Zhai, Yifan
    Sun, Jie
    Jin, Jie
    JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (01)
  • [6] First-in-human open-label study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and other hematologic malignancies
    Ailawadhi, Sikander
    Chen, Zi
    Huang, Bo
    Paulus, Aneel
    Collins, Mary
    Fu, Lei
    Li, Mingyu
    Ahmad, Mohammad
    Men, Lichuang
    Wang, Hengbang
    Davids, Matthew
    Liang, Eric
    Mekala, Divya
    He, Zhicong
    Lasica, Masa
    Yannakou, Costas
    Parrondo, Ricardo
    Glass, Laura
    Yang, Dajun
    Chanan-Khan, Asher
    Zhai, Yifan
    LEUKEMIA & LYMPHOMA, 2023, 64 : S76 - S77
  • [7] Combination of olverembatinib (HQP1351) with BCL-2 inhibitor lisaftoclax (APG-2575) overcomes resistance in gastrointestinal stromal tumors (GISTs)
    Min, Ping
    Wang, Guangfeng
    Liang, Eric
    Wu, Bingxing
    Yu, Huidan
    Yang, Dajun
    Zhai, Yifan
    CANCER RESEARCH, 2023, 83 (07)
  • [8] Synergistic effect of BCL-2 inhibitor APG-2575 and CDK9 inhibitor in acute myeloid leukemia and DLBCL preclinical tumor models
    Fang, Douglas D.
    Tao, Ran
    Tang, Qiuqiong
    Gu, Shoulai
    Zhai, Guoqin
    Li, Jiajun
    Wang, Qixin
    Fang, Xu
    Li, Na
    Yang, Dajun
    Zhai, Yifan
    CANCER RESEARCH, 2019, 79 (13)
  • [9] First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).
    Ailawadhi, Sikander
    Chanan-Khan, Asher Alban Akmal
    Chen, Zi
    Huang, Bo
    Konopleva, Marina
    Brander, Danielle M.
    Rizzieri, David
    Lasica, Masa
    Tam, Constantine Si Lun
    Yannakou, Costas K.
    Prince, H. Miles
    Davids, Matthew Steven
    He, Zhicong
    Lu, Ming
    Ahmad, Mohammad
    Li, Mingyu
    Liang, Zhiyan
    Mudenda, Boyd
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia
    Wenwen Wei
    Shujuan Huang
    Qing Ling
    Shihui Mao
    Yu Qian
    Wenle Ye
    Fenglin Li
    Jiajia Pan
    Xiangjie Lin
    Jiansong Huang
    Xin Huang
    Yifan Zhai
    Jie Sun
    Jie Jin
    Journal of Translational Medicine, 20
12345